Compugen Ltd (CGEN) 9.71 $CGEN
Downtrend Call Working As Compugen Stock Falls 9.6% (CGEN)
Comtex SmarTrend(R) - Tue Apr 15, 10:07AM CDT
SmarTrend identified a Downtrend for Compugen (NASDAQ:CGEN) on March 25th, 2014 at $10.37. In approximately 3 weeks, Compugen has returned 9.60% as of today's recent price of $9.37.
Compugen Statement Regarding Insider Trading Allegations
Business Wire - Mon Apr 07, 8:03AM CDT
Compugen Ltd. (NASDAQ: CGEN) issued the following statement today.
Biosimulation Trends - Global Market Overview 2014-2017
M2 - Thu Apr 03, 10:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bclc3f/biosimulation) has announced the addition of the "Biosimulation Trends" report to their offering. Biosimulation is the mathematical simulation of complex, large biological processes on a computer. Biosimulation is being adopted at a faster pace, to extract and interpret vital data from experiments during drug discovery and development. The report analyzes and presents an overview of Biosimulation market worldwide. The report provides global market estimates and projections for Biosimulation in US dollars for the years 2012 through 2017. Supported with 1 market data table, the report highlights the ever increasing permanence of Biosimulation. The report also provides a review of Biosimulation Models, and Biosimulation software. Key Topics Covered: 1. BIOSIMULATION - A MARKET OVERVIEW - A Prelude - Biosimulation - Revolutionizing Drug Discovery - Biosimulation - Models - Biosimulation Software 2. RECENT INDUSTRY ACTIVITY - Accelrys Introduces Discovery Studio 3.5 - Rhenovia Pharma Introduces Drug Development Programs for Orphan, Neglected and Rare Neurodegenerative Diseases - Rhenovia Pharma Sets Up International Subsidiary in the US - Rhenovia Pharma Inks an Agreement with Portmann - Entelos and RegeneMed Introduce iToxFX Service 3. MARKET PARTICIPANTS - Accelrys, Inc. - Advanced Chemistry Development, Inc. - Anoixis Corporation - Aptiv Solutions - Chemical Computing Group, Inc. - Cognigen Corporation - Compugen Ltd. - Entelos, Inc. - Genedata AG - GNS Healthcare - Immunetrics, Inc. - INOSIM Software GmbH - Insilico Biotechnology AG - Kinetigen, Inc. - LeadInvent - Leadscope, Inc. - Molecular Knowledge Systems, Inc. - Nimbus Discovery LLC - Novo Nordisk A/S - Open Eye Scientific Software, Inc. - Optimata Ltd. - PhinC Development - Physiomics PLC - Rhenovia Pharma SAS - Rosa & Company LLC - Schrodinger LLC - Simcyp Ltd. - Tessella Ltd. - TheraSim - VirtuCel, Inc. 4. APPENDIX For more information visit http://www.researchandmarkets.com/research/bc...simulation
18.3% Return Seen to Date on SmarTrend Compugen Call (CGEN)
Comtex SmarTrend(R) - Thu Mar 20, 11:13AM CDT
SmarTrend identified an Uptrend for Compugen (NASDAQ:CGEN) on January 7th, 2014 at $9.94. In approximately 2 months, Compugen has returned 18.31% as of today's recent price of $11.76.
Will 'Buy' Rating Help Compugen (CGEN) Today?
at The Street - Wed Mar 19, 8:55AM CDT
Compugen CGEN was given a "buy" rating with a price target of $17 by analysts at Jefferies Group.
Compugen Up 14.4% Since SmarTrend Uptrend Call (CGEN)
Comtex SmarTrend(R) - Thu Mar 13, 10:11AM CDT
SmarTrend identified an Uptrend for Compugen (NASDAQ:CGEN) on January 7th, 2014 at $9.94. In approximately 2 months, Compugen has returned 14.39% as of today's recent price of $11.37.
Compugen's Microsoft Licensing Solutions Expertise Reaffirmed
Marketwire - Tue Mar 11, 10:01AM CDT
Compugen Inc. is pleased to announce that as part of Microsoft Canada's comprehensive assessment of its partners' capabilities, Compugen will continue to retain the Licensing Solutions Partner (LSP) Authorization for Canada.
Uptrend Call Working As Compugen Stock Rises 19.7% (CGEN)
Comtex SmarTrend(R) - Thu Mar 06, 9:24AM CST
SmarTrend identified an Uptrend for Compugen (NASDAQ:CGEN) on January 7th, 2014 at $9.94. In approximately 2 months, Compugen has returned 19.72% as of today's recent price of $11.90.
Compugen concludes public offering of 6.9m ordinary shares
M2 - Thu Mar 06, 5:21AM CST
Drug company Compugen (NASDAQ:CGEN) (Tel Aviv:CGEN.TA), based in Israel, revealed on Wednesday the completion of its public offering of 6.9m ordinary shares at a price of USD10.50 per share.
Compugen Ltd. Closes Public Offering of Ordinary Shares
Business Wire - Wed Mar 05, 3:05PM CST
Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) today announced that it has closed its underwritten public offering of 6,900,000 ordinary shares, including 900,000 shares sold pursuant to the full exercise of the underwriters' option to purchase additional shares, at a price to the public of $10.50 per share. Gross proceeds to Compugen are approximately $72.5 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by Compugen.
Compugen prices public offering of ordinary shares at USD10.50 per share
M2 - Mon Mar 03, 4:16AM CST
Drug company Compugen (NASDAQ:CGEN) (Tel Aviv:CGEN.TA) said on Friday that it has priced a public offering of 6,000,000 ordinary shares at USD10.50 per share.
Nasdaq stocks posting largest volume increases
AP - Fri Feb 28, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Nasdaq stocks posting largest percentage decreases
AP - Fri Feb 28, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Why Compugen Ltd. Shares Got Hammered
Sean Williams, The Motley Fool - Motley Fool - Fri Feb 28, 12:44PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Compugen , a biopharmaceutical company...
Compugen Ltd. Prices Public Offering of Ordinary Shares
Business Wire - Fri Feb 28, 8:15AM CST
Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) today announced that it has priced an underwritten public offering of 6,000,000 ordinary shares at a price to the public of $10.50 per share. Gross proceeds to Compugen are expected to be $63 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by Compugen. The offering is expected to close on or about March 5, 2014, subject to satisfaction of customary closing conditions. Compugen has granted the underwriters a thirty (30) day option to purchase up to 900,000 additional ordinary shares.
Compugen plans to issue ordinary shares in public offering
M2 - Fri Feb 28, 3:05AM CST
Drug company Compugen (NASDAQ:CGEN) (Tel Aviv:CGEN.TA) reported on Thursday the start of an underwritten public offering of its ordinary shares.
Compugen Ltd. Announces Proposed Public Offering of Ordinary Shares
Business Wire - Thu Feb 27, 3:17PM CST
Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) today announced that it has commenced an underwritten public offering of its ordinary shares. All of the ordinary shares in the offering are being offered by Compugen. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Downtrend Call Working As Compugen Stock Falls 9.6% (CGEN)
Comtex SmarTrend(R) - Tue Apr 15, 10:07AM CDT
SmarTrend identified a Downtrend for Compugen (NASDAQ:CGEN) on March 25th, 2014 at $10.37. In approximately 3 weeks, Compugen has returned 9.60% as of today's recent price of $9.37.
Compugen Statement Regarding Insider Trading Allegations
Business Wire - Mon Apr 07, 8:03AM CDT
Compugen Ltd. (NASDAQ: CGEN) issued the following statement today.
Biosimulation Trends - Global Market Overview 2014-2017
M2 - Thu Apr 03, 10:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bclc3f/biosimulation) has announced the addition of the "Biosimulation Trends" report to their offering. Biosimulation is the mathematical simulation of complex, large biological processes on a computer. Biosimulation is being adopted at a faster pace, to extract and interpret vital data from experiments during drug discovery and development. The report analyzes and presents an overview of Biosimulation market worldwide. The report provides global market estimates and projections for Biosimulation in US dollars for the years 2012 through 2017. Supported with 1 market data table, the report highlights the ever increasing permanence of Biosimulation. The report also provides a review of Biosimulation Models, and Biosimulation software. Key Topics Covered: 1. BIOSIMULATION - A MARKET OVERVIEW - A Prelude - Biosimulation - Revolutionizing Drug Discovery - Biosimulation - Models - Biosimulation Software 2. RECENT INDUSTRY ACTIVITY - Accelrys Introduces Discovery Studio 3.5 - Rhenovia Pharma Introduces Drug Development Programs for Orphan, Neglected and Rare Neurodegenerative Diseases - Rhenovia Pharma Sets Up International Subsidiary in the US - Rhenovia Pharma Inks an Agreement with Portmann - Entelos and RegeneMed Introduce iToxFX Service 3. MARKET PARTICIPANTS - Accelrys, Inc. - Advanced Chemistry Development, Inc. - Anoixis Corporation - Aptiv Solutions - Chemical Computing Group, Inc. - Cognigen Corporation - Compugen Ltd. - Entelos, Inc. - Genedata AG - GNS Healthcare - Immunetrics, Inc. - INOSIM Software GmbH - Insilico Biotechnology AG - Kinetigen, Inc. - LeadInvent - Leadscope, Inc. - Molecular Knowledge Systems, Inc. - Nimbus Discovery LLC - Novo Nordisk A/S - Open Eye Scientific Software, Inc. - Optimata Ltd. - PhinC Development - Physiomics PLC - Rhenovia Pharma SAS - Rosa & Company LLC - Schrodinger LLC - Simcyp Ltd. - Tessella Ltd. - TheraSim - VirtuCel, Inc. 4. APPENDIX For more information visit http://www.researchandmarkets.com/research/bc...simulation
18.3% Return Seen to Date on SmarTrend Compugen Call (CGEN)
Comtex SmarTrend(R) - Thu Mar 20, 11:13AM CDT
SmarTrend identified an Uptrend for Compugen (NASDAQ:CGEN) on January 7th, 2014 at $9.94. In approximately 2 months, Compugen has returned 18.31% as of today's recent price of $11.76.
Will 'Buy' Rating Help Compugen (CGEN) Today?
at The Street - Wed Mar 19, 8:55AM CDT
Compugen CGEN was given a "buy" rating with a price target of $17 by analysts at Jefferies Group.
Compugen Up 14.4% Since SmarTrend Uptrend Call (CGEN)
Comtex SmarTrend(R) - Thu Mar 13, 10:11AM CDT
SmarTrend identified an Uptrend for Compugen (NASDAQ:CGEN) on January 7th, 2014 at $9.94. In approximately 2 months, Compugen has returned 14.39% as of today's recent price of $11.37.
Compugen's Microsoft Licensing Solutions Expertise Reaffirmed
Marketwire - Tue Mar 11, 10:01AM CDT
Compugen Inc. is pleased to announce that as part of Microsoft Canada's comprehensive assessment of its partners' capabilities, Compugen will continue to retain the Licensing Solutions Partner (LSP) Authorization for Canada.
Uptrend Call Working As Compugen Stock Rises 19.7% (CGEN)
Comtex SmarTrend(R) - Thu Mar 06, 9:24AM CST
SmarTrend identified an Uptrend for Compugen (NASDAQ:CGEN) on January 7th, 2014 at $9.94. In approximately 2 months, Compugen has returned 19.72% as of today's recent price of $11.90.
Compugen concludes public offering of 6.9m ordinary shares
M2 - Thu Mar 06, 5:21AM CST
Drug company Compugen (NASDAQ:CGEN) (Tel Aviv:CGEN.TA), based in Israel, revealed on Wednesday the completion of its public offering of 6.9m ordinary shares at a price of USD10.50 per share.
Compugen Ltd. Closes Public Offering of Ordinary Shares
Business Wire - Wed Mar 05, 3:05PM CST
Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) today announced that it has closed its underwritten public offering of 6,900,000 ordinary shares, including 900,000 shares sold pursuant to the full exercise of the underwriters' option to purchase additional shares, at a price to the public of $10.50 per share. Gross proceeds to Compugen are approximately $72.5 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by Compugen.
Compugen prices public offering of ordinary shares at USD10.50 per share
M2 - Mon Mar 03, 4:16AM CST
Drug company Compugen (NASDAQ:CGEN) (Tel Aviv:CGEN.TA) said on Friday that it has priced a public offering of 6,000,000 ordinary shares at USD10.50 per share.
Nasdaq stocks posting largest volume increases
AP - Fri Feb 28, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Nasdaq stocks posting largest percentage decreases
AP - Fri Feb 28, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Why Compugen Ltd. Shares Got Hammered
Sean Williams, The Motley Fool - Motley Fool - Fri Feb 28, 12:44PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Compugen , a biopharmaceutical company...
Compugen Ltd. Prices Public Offering of Ordinary Shares
Business Wire - Fri Feb 28, 8:15AM CST
Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) today announced that it has priced an underwritten public offering of 6,000,000 ordinary shares at a price to the public of $10.50 per share. Gross proceeds to Compugen are expected to be $63 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by Compugen. The offering is expected to close on or about March 5, 2014, subject to satisfaction of customary closing conditions. Compugen has granted the underwriters a thirty (30) day option to purchase up to 900,000 additional ordinary shares.
Compugen plans to issue ordinary shares in public offering
M2 - Fri Feb 28, 3:05AM CST
Drug company Compugen (NASDAQ:CGEN) (Tel Aviv:CGEN.TA) reported on Thursday the start of an underwritten public offering of its ordinary shares.
Compugen Ltd. Announces Proposed Public Offering of Ordinary Shares
Business Wire - Thu Feb 27, 3:17PM CST
Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) today announced that it has commenced an underwritten public offering of its ordinary shares. All of the ordinary shares in the offering are being offered by Compugen. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
